The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group
Abstract
Objective: The use of hydroxychloroquine (HCQ) in pregnancy remains controversial. The recent demonstration that HCQ passes across the placenta, with cord blood concentrations nearly identical to those found in maternal blood, emphasizes the need for careful evaluation of pregnancies in women receiving HCQ. However, only small series of HCQ‐treated pregnant women have been reported, and most of these studies had no control group. We now report our experience with 133 pregnancies in women being treated with HCQ, resulting in 117 live births. Results in the HCQ group are compared with those in a control group. Methods: One hundred thirty‐three consecutive pregnancies in 90 women treated with 200 mg of HCQ either twice daily (122 pregnancies) or once daily (11 pregnancies) were studied. These pregnancies were compared with 70 consecutive pregnancies in 53 women with similar disorders who did not receive HCQ. Electrocardiography was performed in 47 children of mothers treated with HCQ and in 45 children in the control group. Results: Eighty‐eight percent of pregnancies in the HCQ group and 84% of those in the control group ended successfully with a live birth. The outcomes of pregnancy were not statistically different between groups. One child in each group died of causes related to prematurity. Three malformations were observed in the HCQ group (1 hypospadias, 1 craniostenosis, and 1 cardiac malformation) versus 4 in the control group. On the electrocardiograms, the PR interval and the corrected QT interval were not statistically different between groups. No visual, hearing, growth, or developmental abnormalities were reported in any of the children at the last follow‐up (ages 12–108 months; mean age 26 months). Conclusion: Our findings support preliminary evidence for the safety of HCQ therapy during pregnancy. This treatment probably should be maintained throughout pregnancy in patients with systemic lupus erythematosus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Vitali, C., Bombardieri, S., Moutsopoulos, H. M., Balestrieri, G., Bencivelli, W., Bernstein, R. M., Bjerrum, K. B., Braga, S., Coll, J., Vita, S. D., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360309 · Cited by 1,436
(1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240303 · Cited by 677
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
Levy, R. A., Vilela, V. S., Cataldo, M. J., Ramos, R. C., Duarte, J. L., Tura, B. R., Albuquerque, E. M., & Jesús, N. R. (2001) · Lupus · doi:10.1191/096120301678646137 · Cited by 398
Bioavailability of hydroxychloroquine tablets in healthy volunteers.
Tett, S., Cutler, D., Day, R., & Brown, K. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03439.x · Cited by 269
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
Buchanan, N. M., Toubi, E., Khamashta, M. A., Lima, F., Kerslake, S., & Hughes, G. R. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.7.486 · Cited by 161
The Safety of Antimalarial Drugs in Pregnancy
Phillips‐Howard, P. A., & Wood, D. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00001 · Cited by 150
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases
Klinger, G., Morad, Y., Westall, C. A., Laskin, C. A., Spitzer, K. A., Koren, G., Ito, S., & Buncic, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06004-4 · Cited by 148
Evidence of transplacental passage of hydroxychloroquine in humans
Costedoat-Chalumeau, N., Amoura, Z., Aymard, G., Huong, D. U. L. T., Wechsler, B., Vauthier-Brouzes, D., Dermer, M. E., Darbois, Y., & Pietté, J. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10150 · Cited by 116
Self-citationHydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Parke, A. L., & West, B. (1996) · PubMed · Cited by 107
Cited by
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 543
Hydroxychloroquine in lupus pregnancy
Clowse, M. E. B., Magder, L., Witter, F., & Petri, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22159 · Cited by 529
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
Metadata
- Authors
- Costedoat‐Chalumeau, N., Amoura, Z., Duhaut, P., Huong, D. L. T., Sebbough, D., Wechsler, B., Vauthier, D., Denjoy, I., Lupoglazoff, J., & Piette, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-11
- Volume
- 48
- Issue
- 11
- Pages
- 3207-3211
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2056493149
- Cited by
- 314
- References
- 14
- FWCI
- 20.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group. https://app.cochat.ai/papers/10.1002/art.11304
- The paper
- Costedoat‐Chalumeau, N., Amoura, Z., Duhaut, P., Huong, D. L. T., Sebbough, D., Wechsler, B., Vauthier, D., Denjoy, I., Lupoglazoff, J., & Piette, J. (2003). Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group. Arthritis & Rheumatism. https://doi.org/10.1002/art.11304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.